Xponance’s Akero Therapeutics AKRO Stock Holding History

Xponance’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,488	Closed	-$261K	–	1572
2025 Q3	$261K	Buy	5,488 +24	+0.4%	+$1.16K	﹤0.01%	1234
2025 Q2	$292K	Sell	5,464 -101	-2%	-$4.59K	﹤0.01%	1155
2025 Q1	$225K	Buy	+5,565	New	+$236K	﹤0.01%	1226

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Xponance's AKRO Position: Q4 2025 in Review

Xponance sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 5,488 shares — an estimated $261K sold.

Xponance first reported a position in AKRO in Q1 2025 and held it in 3 quarters. The position peaked at $292K in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Xponance reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Xponance sold 5,488 Akero Therapeutics shares in Q4 2025, an estimated $261K.
Xponance first reported a position in Akero Therapeutics in Q1 2025 and held it in 3 quarters.
Xponance's Akero Therapeutics position peaked at $292K in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Xponance's 13F filing for Q4 2025, filed 12 Feb 2026.